photo of

Details

Role Group Leader / Honorary Fellow Manager
Research area Genomic Medicine
Group Molecular Therapies

Top Publications

  • Savarirayan, R, Hoernschemeyer, DG, Ljungberg, M, Zarate, YA, Bacino, CA, Bober, MB, Legare, JM, Högler, W, Quattrin, T, Abuzzahab, MJ, et al. Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial. EClinicalMedicine 65: 102258 2023
    view publication
  • Savarirayan, R, De Bergua, JM, Arundel, P, Salles, JP, Leiva-Gea, A, Irving, M, Saraff, V, McDevitt, H, Salcedo, M, Nicolino, MP, et al. THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib. Journal of the Endocrine Society 7(Supplement_1) : bvad114.1432 2023
    view publication
  • Savarirayan, R, De Bergua, JM, Arundel, P, McDevitt, H, Cormier-Daire, V, Saraff, V, Skae, M, Delgado, B, Leiva-Gea, A, Salcedo, M, et al. THU165 PROPEL, PROPEL 2 And PROPEL OLE Studies Of Infigratinib In Children With Achondroplasia: Design And Status Of 3 Ongoing Trials. Journal of the Endocrine Society 7(Supplement_1) : bvad114.1416 2023
    view publication
  • Savarirayan, R, McDonnell, C, Hoernschemeyer, DG, Hove, HB, Zarate, YA, Bober, MB, Bacino, CA, Legare, JM, Högler, W, Quattrin, T, et al. THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. Journal of the Endocrine Society 7(Supplement_1) : bvad114.1408 2023
    view publication
  • Savarirayan, R, De Bergua, JM, Arundel, P, Salles, JP, Saraff, V, Delgado, B, Leiva-Gea, A, McDevitt, H, Nicolino, MP, Rossi, M, et al. OR27-03 Oral Infigratinib Treatment Is Well Tolerated And Significantly Increases Height Velocity In Children With Achondroplasia: Month 6 Results From The PROPEL 2 Dose-finding Study. Journal of the Endocrine Society 7(Supplement_1) : bvad114.1525 2023
    view publication

Page 5 of 51

Related links